REFERENCES
3. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.
4. Sapon-Cousineau V, Sapon-Cousineau S, Assouline S. PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma. Curr Treat Options Oncol. 2020;21:51.
5. Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196:316-28.
6. Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid leukemia. Hemasphere. 2021;5:e572.
7. Chen X, Shao W, Huang H, Feng X, Yao S, Ke H. Overexpression of RCN1 correlates with poor prognosis and progression in non-small cell lung cancer. Hum Pathol. 2019;83:140-8.
8. Liu X, Zhang N, Wang D, et al. Downregulation of reticulocalbin‐1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells. Cancer Sci. 2018;109:1147-57.
9. Wang JW, Ma L, Liang Y, et al. RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α-XBP1s pathway. Cell Death Discov. 2021;7:298.
10. Krause F, Stoffel M, Winterhagen FI, et al. Reticulocalbin-1 in clear cell renal cell carcinoma: clinical and functional evidence for its role as a biomarker and potential therapeutic target. BMC Cancer. 2025;25:1425.
11. Deng S, Pan Y, An N, et al. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells. Mol Oncol. 2023;17:2584-602.
12. Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142-9.
13. Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215:1287-99.
14. Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26-39.
15. Gulen MF, Koch U, Haag SM, et al. Signalling strength determines proapoptotic functions of STING. Nat Commun. 2017;8:427.
16. Pérez-Treviño P, Velásquez M, García N. Mechanisms of mitochondrial DNA escape and its relationship with different metabolic diseases. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165761.
17. Xiong Y, Leng Y, Tian H, et al. Decreased MFN2 activates the cGAS-STING pathway in diabetic myocardial ischaemia-reperfusion by triggering the release of mitochondrial DNA. Cell Commun Signal. 2023;21:192.
18. Li Y, Yang Q, Chen H, et al. TFAM downregulation promotes autophagy and ESCC survival through mtDNA stress-mediated STING pathway. Oncogene. 2022;41:3735-46.
19. Ding K, Zhang L, Zhang Y, et al. TFAM deficiency triggers mtDNA leakage and cGAS-STING-mediated intestinal ischemia-reperfusion injury. Inflammation. 2025;48:3942-58.
20. Kanki T, Ohgaki K, Gaspari M, et al. Architectural role of mitochondrial transcription factor A in maintenance of human mitochondrial DNA. Mol Cell Biol. 2004;24:9823-34.
21. Hu M, Zhou M, Bao X, et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J Clin Invest. 2021;131:139333.
22. Wang C, Zhang R, He J, et al. Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. Nat Commun. 2023;14:3877.
23. Weiss WA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol. 2007;3:739-44.
24. Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, Wong GK. Recent update on siRNA therapeutics. Int J Mol Sci. 2025;26:3456.
25. Tatiparti K, Sau S, Kashaw SK, Iyer AK. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7:77.
26. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265-80.
27. Knudsen KB, Northeved H, Kumar PE, et al. In vivo toxicity of cationic micelles and liposomes. Nanomedicine. 2015;11:467-77.
28. Cummings JC, Zhang H, Jakymiw A. Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment. Transl Res. 2019;214:92-104.
29. Li Q, Ding Y, Shi Y, et al. 80 years of extracellular vesicles: from discovery to clinical translation. Extracell Vesicles Circ Nucl Acids. 2026;7:165-233.
30. Usman WM, Pham TC, Kwok YY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9:2359.
31. Peng B, Nguyen TM, Jayasinghe MK, et al. Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy. J Extracell Vesicles. 2022;11:e12187.
32. Chen H, Jayasinghe MK, Yeo EYM, et al. CD33‐targeting extracellular vesicles deliver antisense oligonucleotides against FLT3‐ITD and miR‐125b for specific treatment of acute myeloid leukaemia. Cell Prolif. 2022;55:e13255.
33. Ishihara T, Ban-Ishihara R, Ota A, Ishihara N. Mitochondrial nucleoid trafficking regulated by the inner-membrane AAA-ATPase ATAD3A modulates respiratory complex formation. Proc Natl Acad Sci U S A. 2022;119:e2210730119.
34. Huang D, Chen S, Xiong D, et al. Mitochondrial dynamics: working with the cytoskeleton and intracellular organelles to mediate mechanotransduction. Aging Dis. 2023;14:1511-32.
35. Chen L, Li Y, Zambidis A, Papadopoulos V. ATAD3A: a key regulator of mitochondria-associated diseases. Int J Mol Sci. 2023;24:12511.
36. Brar KK, Hughes DT, Morris JL, et al. PERK-ATAD3A interaction provides a subcellular safe haven for protein synthesis during ER stress. Science. 2024;385:eadp7114.
37. Teng Y, Ren X, Li H, Shull A, Kim J, Cowell JK. Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein. Oncogene. 2016;35:333-43.
38. Nouri Z, Fakhri S, Nouri K, Wallace CE, Farzaei MH, Bishayee A. Targeting multiple signaling pathways in cancer: the rutin therapeutic approach. Cancers. 2020;12:2276.
